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Abstract 
 
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a relatively new autoimmune disorder of the central 
nervous system. We report the first case of anti-NMDAR autoimmune encephalitis combined with anti-voltage-gated 
potassium channel (anti-VGKC) antibodies in Lithuania in a 16-year-old girl. The patient was admitted to psychiatry unit 
because of an acute psychotic episode. She was unsuccessfully treated with antipsychotics, and electroconvulsive therapy was 
initiated because of her rapidly deteriorating condition. Electroconvulsive therapy improved the patient’s condition even 
before the initiation of immunomodulatory therapy. The abrupt onset, atypical and severe course of psychosis, poor response 
to antipsychotic treatment, and signs of flu-like prodromal period led to the search of non-psychiatric causes. Although with 
considerable delay, she was screened for an autoimmune encephalitis. Positive anti-NMDA receptor antibodies were found 
in the cerebrospinal fluid, but not in serum. In addition, serum was found positive for antinuclear antibodies and anti-VGKC 
antibodies but negative for CASPR2 and LGI1 antibodies. The girl was treated with intravenous immunoglobulin and 
methylprednisolone with satisfactory response, although infrequent orofacial movements, emotional lability, and learning 
deficits remained upon discharge. The reported case suggests that multiple antibodies could be present, and that 
electroconvulsive therapy may have a role in symptomatic treatment of autoimmune encephalitis.  
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Introduction 
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) 
encephalitis is a relatively newly discovered disorder 
with progressive clinical course and attainable 
treatment efficacy (1,2). The first cases of non-
infectious limbic encephalitis of reversible nature 
associated with ovarian teratoma were reported in a 
young woman and an adolescent girl in 1997 (3,4). 
Description of antibodies against synaptic NMDA 
receptors causing this autoimmune illness soon 
followed (5). Anti-NMDAR encephalitis has since 
been observed also in cases without teratoma, in both 
genders, and in all ages (from eight months to 85 
years) (1). Among them, up to 40% of reported cases 
have occurred under the age of 18 years (1). In 
infants and young children, the clinical presentation 
more often starts with neurological symptoms, such 
as abnormal movements or seizures (6,7). In 
adolescents, the disease may be more obscure due to 
initial manifestation of psychiatric symptoms or 
cognitive dysfunction leading to the delayed 
therapeutic interventions. If untreated, anti-
NMDAR encephalitis can be a devastating disease. 
However, immunotherapy has shown favorable 
outcomes in 81% of patients (1). Thus, awareness of 
anti-NMDAR encephalitis in the differential 
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diagnosis of acute adolescent psychosis is of great 
importance. 
Encephalitis with anti-voltage-gated potassium 
channel (anti-VGKC) complex antibodies is a rare 
condition (7,8). The anti-VGKC antibodies are 
directed against the VGKC-complex proteins, which 
include leucine-rich glioma inactivated 1 (LGI1), 
contactin-associated protein-2 (CASPR2), and other 
proteins (9). The clinical characteristics of 
encephalitis, such as seizures, memory loss, sleep 
disturbance, as well as laboratory findings of 
hyponatremia, inflammatory cerebrospinal fluid 
(CSF), temporal lobe abnormalities on magnetic 
resonance imaging (MRI), and abnormal 
electroencephalography (EEG) have been previously 
described (10). A case of autoimmune encephalitis 
seropositive for NMDAR and VGKC antibodies has 
been reported; however, the role of multiple 
antibodies in the clinical course of disease is not well 
understood (11).  
It is extremely important to target both 
pathogenesis and clinical syndrome of the 
encephalitis to achieve successful recovery. In case of 
teratoma-associated anti-NMDAR encephalitis, it is 
crucial to remove tumor to improve symptoms. 
Although specific immunotherapy regimens and 
their long-term outcomes have not been validated, 
early immunotherapy and a second-line therapy have 
been associated with fewer relapses (1). The first-line 
treatment is immunotherapy with corticosteroids, 
intravenous immunoglobulins, a combination of 
both, or plasmapheresis (12). There is evidence that 
therapeutic apheresis is particularly effective in 
patients with antibodies against neuronal surface 
structures and treatment outcomes do not correlate 
with the timing of intervention (13). After 
unsuccessful or incomplete recovery from the first-
line therapy there are several strategies for further 
treatment. Rituximab has been increasingly reported 
as a relatively safe and effective drug of choice in 
pediatric anti-NMDAR encephalitis cases (12). 
Immunosuppression with cyclophosphamide is a 
second frequently reported drug of choice (12).  
An autoimmune encephalitis is a well described 
and potentially treatable condition, which requires 
early recognition and intervention. In many clinical 
settings first-line treatment initiation usually is based 
on the clinical diagnosis because awaiting results of 
serologic studies could delay treatment (12). 
Therefore, clinical suspicion and awareness of 
autoimmune condition as a cause of acute psychosis 
are essential. As antibody-associated autoimmune 
encephalitis is a relatively new entity in child and 
adolescent psychiatry there is an urgent need for 
increased awareness among clinicians dealing with 
acute psychiatric conditions in children and 
adolescents. The presented case of autoimmune 
encephalitis is remarkable because of acute 
presentation, the effectiveness of electroconvulsive 
therapy (ECT), positive tests for multiple antibodies 
against neuronal structures late in the course of the 
disease, concomitant autoimmune thyroiditis, and 
favorable outcome despite delayed immunotherapy. 
The authors believe that this case represents a 
classical picture of anti-NMDAR encephalitis with 
common problems arising in a clinical setting.  
 
Clinical case report 
A 16-year-old girl was admitted to psychiatry 
intensive care unit because of the first acute 
psychotic episode. Over the last year, the girl had 
been reporting various minor health problems such 
as fatigue, joint pain, muscle tenderness, oily skin, 
and constant subfebrile temperature. Mild thyroid 
hypofunction was found, and the girl was diagnosed 
with autoimmune thyroiditis and was prescribed L-
thyroxin. Subtle changes in the patient’s mood, 
behavior, and cognitive functions preceded a month 
before the sudden manifestation of psychosis. The 
girl also reported weight loss of about 4 kg in one 
month. 
On admission, the patient was severely agitated. 
Vital signs were normal as well as head computed 
tomographic scan and routine laboratory 
examinations. Thyroid hormone levels were also 
normal. She was seronegative for tick-borne 
encephalitis virus and Borrelia burgdorferi (tested IgM 
and IgG, ELISA). Because of the progression to 
oneiroid syndrome the patient was put on 
intravenous haloperidol 2.5 mg/day plus 
trihexyphenidyl 2 mg/day, which induced 
extrapyramidal symptoms on the second day of 
treatment. The patient’s condition continued to 
deteriorate; she became fully disoriented in time and 
place and had excessive perceptual anomalies with 
vivid visual and auditory hallucinations. The speech 
disturbances rapidly progressed to partial mutism 
and inability to read and write. Episodic posturing, 
orofacial dyskinesia, stereotypical hand movements, 
autonomic dysfunction (severe blood pressure 
fluctuations), and subfebrile temperature were 
observed. Severe insomnia was resistant to treatment 
with benzodiazepines and lasted for two weeks. An 
early onset of extrapyramidal side effects and fully 
developed positive psychotic symptoms while on 
haloperidol have led to the therapy change. The 
patient was prescribed intravenous olanzapine, 
which was later changed to oral quetiapine, but 
psychotic symptoms were refractory to the 
antipsychotic treatment. ECT is not a common 
choice in the clinical practice of adolescent 
psychiatry, but in the light of life-threatening 
catatonia and ineffective treatment with several 
antipsychotics, the patient was given eight 
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procedures of ECT. On the fifth week of acute illness 
the patient’s clinical status finally started to improve. 
Severe course of psychosis and resistance to 
antipsychotic therapy warranted further diagnostic 
evaluation. Autonomic dysfunction, subfebrile 
temperature, and stereotypies in association with 
acute psychosis caused the suspicion of autoimmune 
encephalitis. On the fourth week of illness serum was 
tested for anti-NMDAR antibodies and found to be 
negative (test was performed at Gemeinschaftslabor 
Cottbus, Lübbenau, Germany). Brain MRI (1.5 T) 
showed no pathologic changes. EEG showed 
intermittent slow delta-theta wave activity in 
parietotemporal and centrofrontal regions. Extensive 
tumor screening (ultrasound of the urogenital 
system, abdominal and pelvic MRI, and chest 
computed tomographic scan) was negative. 
Further, an immunological examination was 
performed. It included blood serum measurements 
for antinuclear, anti-dsDNA, anti-ribosomal P, anti-
cardiolipin, and anti-beta2 glycoprotein-I antibodies. 
Only antinuclear antibodies were found positive 
(dilution > 1:200, immunofluorescence method, 
local diagnostic laboratory) and remained positive on 
repeated testing after three months. On the fourth 
month of illness serum test was repeated for anti-
NMDAR antibodies and was also negative; however, 
a CSF sample showed positive oligoclonal bands and 
was found positive for anti-NMDAR antibodies 
(indirect immunofluorescence at Eurodiagnostica 
Wieslab, Malmo, Sweden). In addition, blood serum 
was tested for antibodies against VGKC-complex 
(including CASPR2 and LGI1) and GABA-b 
receptors and was found positive for VGKC, with a 
value of 394 pmol/l for the latter 
(radioimmunoprecipitation method; the result is 
considered clinically significant if value is over 300 
pmol/l; Eurodiagnostica Wieslab) (Figure 1). 
 
 
 
 
 
FIGURE 1. Evolution of clinical symptoms and response to treatment. Anti-NMDAR, anti-N-methyl-D-aspartate receptor; CSF, cerebrospinal fluid; EEG, 
electroencephalography; VGKC, voltage-gated potassium channel. 
 
 
 
The patient received immunotherapy with 
intravenous methylprednisolone (five pulses of 1 g 
daily) and IVIG (five pulses of 0.4 g/kg daily). At that 
time, the only remaining symptoms were occasional 
orofacial movements while asleep and mild learning 
difficulties. The patient continued quetiapine 300 
mg/day for several months and was medication free 
nine months after the manifestation of disease. 
NMDAR antibodies in CSF were still positive on 
the tenth month of disease; however, anti-VGKC 
antibodies in serum were negative. The patient’s 
mental status, however, remained normal. At follow 
up after a year, the patient reported mild memory 
problems. The outcome was categorized as full 
clinical recovery. 
Informed consent of the family was obtained for 
the case report according to the national and 
institutional ethical rules. 
 
Discussion 
We report the representative case of an adolescent 
girl with autoimmune encephalitis manifesting with 
severe acute psychosis that progressed from initial 
psychiatric symptoms to memory disturbance, 
dyskinesia, and catatonia. The clinical course, EEG 
findings, and normal MRI were consistent with 
published data (6,14,15). Negative anti-NMDAR 
serum sample results and positive findings in CSF 
were reported in recent literature, especially early in 
the disease course (16). Uncommon findings of anti-
NMDAR and anti-VGKC in the same patient were 
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previously described (6), but not in a case of 
adolescent with an acute psychotic episode. 
According to current knowledge, positive test for 
anti-VGKC antibodies without evidence of CASPR2 
or LGI1 antibodies production is of doubtful clinical 
relevance (8). Therefore, the authors believe that the 
most likely explanation of clinical symptoms and 
findings in the reported case is anti-NMDAR 
encephalitis with false positive anti-VGKC 
antibodies. Although the reported case started to 
improve even before the immunotherapy, physicians 
made the rather difficult decision to introduce 
treatment. This was based on the increasing 
knowledge that anti-NMDAR encephalitis tends to 
relapse more frequently if treatment is incomplete 
during the manifestation of illness and anti-NMDAR 
antibodies persist (1,17). Improvement of mental 
status may be attributed to positive effects of ECT. 
It has been reported that ECT may lead to significant 
reduction or resolution in psychiatric symptoms in 
anti-NMDA encephalitis, although the physiological 
basis for this has not been defined (18-21).  
According to several authors, an initial assessment 
of patient presenting with first psychosis episode 
should include early serum and/or CSF testing for 
antibodies against the NMDA receptor and other 
antineuronal antibodies (22-24). Until now there are 
no well-described clinical characteristics for selection 
of antibody-mediated encephalitis cases; hence, the 
only way to detect these patients is to screen all cases 
with first-episode psychosis at presentation (25). 
Delayed diagnosis and late introduction of treatment 
are worldwide issues in the management of 
autoimmune encephalitis because of its complicated 
diagnostic process and the lack of pathognomonic 
clinical clues (26,27). The widening gap between 
child and adolescent psychiatry and neurology could 
lead to delayed diagnosis and late start of therapy in 
these patients with psychosis of autoimmune 
etiology. Initiation of treatment early in the course of 
the disease is proven to result in better outcomes 
(28,29); therefore, child and adolescent psychiatrists 
need to take a pro-active role in diagnosing 
autoimmune encephalitis when providing care for 
patients with first episode of acute psychosis. 
 
Conclusions 
In the reported case, anti-NMDAR- and anti-
VGKC-positive encephalitis was diagnosed, and 
immunotherapy was introduced three months after 
the manifestation of psychiatric symptoms. 
Improvement of mental status before the start of 
immunotherapy occurred, and this may be attributed 
to positive effects of ECT. However, based on the 
increasing knowledge that anti-NMDAR encephalitis 
tends to relapse more frequently in untreated cases, 
intravenous methylprednisolone and IVIG were 
prescribed. The authors share a common concern 
that a widening gap between neurology and 
adolescent and child psychiatry could lead to delayed 
diagnosis and late start of therapy in the patients with 
psychosis of autoimmune etiology. 
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